Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events

Wataru Ohashi, Hiroshi Tanaka

研究成果: Article査読

9 被引用数 (Scopus)

抄録

Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost-benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet. The purpose of this study is to investigate advantages obtained by introducing PGx in clinical trials. Particularly, taking Warfarin as an example, we investigate benefits of Enrichment effect that raises response rate of the drug by PGx. When response rate is raised by only 5%, cost of a clinical trial can be reduced to about 40% of a conventional clinical trial. Furthermore, since period necessary for a trial also can be reduced, development period can be shortened by about 750 days. In summary, PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole.

本文言語English
ページ(範囲)701-707
ページ数7
ジャーナルJournal of Medical Systems
34
4
DOI
出版ステータスPublished - 2010 8月 1

ASJC Scopus subject areas

  • 医学(その他)
  • 情報システム
  • 健康情報学
  • 健康情報管理

フィンガープリント

「Benefits of pharmacogenomics in drug development-earlier launch of drugs and less adverse events」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル